The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Net loss | -7,329 | -50,182 |
| Depreciation | 183 | 1,425 |
| Gain on sale of equipment | 133 | -1,915 |
| Stock-based compensation | 1,064 | 8,135 |
| Non-cash lease (gain) expense | - | 489 |
| Change in fair value of warrant liabilities | - | -787 |
| Non-cash lease expense | 128 | - |
| Change in accrued interest and net accretion of discounts on short-term investments | -6 | 188 |
| Prepaid expenses and other current assets | -320 | -809 |
| Accounts payable | 136 | -272 |
| Accrued expenses | -286 | -4,227 |
| Right-of-use assets | - | 5,285 |
| Lease liabilities | -441 | -6,520 |
| Other current liabilities | -21 | - |
| Other noncurrent assets | -6 | -20 |
| Net cash used in operating activities | -6,325 | -45,076 |
| Purchases of property and equipment | 9 | 132 |
| Proceeds from sale of equipment | 133 | - |
| Purchases of available-for-sale investments | 1,216 | 21,340 |
| Proceeds from sales and maturities of available-for-sale investments | 6,152 | 53,619 |
| Net cash provided by investing activities | 5,060 | 32,147 |
| Proceeds from issuance of class a common stock and pre-funded warrants in connection with registered direct offering | - | 5,865 |
| Issuance costs related to issuance of class a common stock and pre-funded warrants in connection with registered direct offering | - | 696 |
| Proceeds from note payable | - | 576 |
| Repayments on note payable | 154 | 51 |
| Proceeds from exercise of stock options | - | 67 |
| Net cash (used in) provided by financing activities | -154 | 5,761 |
| Change in cash, cash equivalents and restricted cash | -1,419 | -7,168 |
| Cash, cash equivalents and restricted cash, beginning of period | 3,505 | 10,673 |
| Cash, cash equivalents and restricted cash, end of period | 2,086 | 3,505 |
Vicarious Surgical Inc. (RBOTW)
Vicarious Surgical Inc. (RBOTW)